
People
Our group includes learners and staff with backgrounds in pharmacology, biochemistry/chemical biology, cell biology, engineering, and pharmaceutics. Our graduate students are part of the Pharmaceutical Sciences graduate program, and we welcome undergraduate students from Pharmaceutical Chemistry, Pharmacology, and other programs at the University of Toronto. Interested in joining us? Please contact Dr. Corson to enquire about available opportunities
Meet Our Team

Dr. Tim Corson
Principal Investigator
Dr. Corson is a Professor and Co-Director, Graduate Department of Pharmaceutical Sciences at the Leslie Dan Faculty of Pharmacy at the University of Toronto, Canada. He is also a Professor of Ophthalmology and Vision Sciences at UofT and an Affiliate Scientist at the Donald K. Johnson Eye Institute, Krembil Research Institute, University Health Network. He holds HonBSc, MSc, and PhD degrees from the University of Toronto, and completed a CIHR-funded postdoctoral fellowship in chemical biology with Craig Crews at Yale University. He established his lab in 2010 at Indiana University School of Medicine in the Department of Ophthalmology, where he became Vice-Chair for Basic and Translational Research, before serving as Chair of the Department of Pharmacology and Toxicology, where he continues to hold an adjunct appointment. He is an author on over 100 publications and an inventor on 12 patents with intellectual property optioned and/or licensed to multiple companies. His lab is currently supported by NSERC, CFI, R01 grants from the US National Institutes of Health (NIH), plus foundation grants. Selected awards include the Merrill Grayson Senior Chair and a Showalter Scholar at the Indiana University School of Medicine, an Entrepreneur-in-Residence at the Indiana Center for Biomedical Innovation, and a Watanabe Translational Scholar of the Indiana Clinical and Translational Sciences Institute. He is on the editorial board of several journals and currently serves as a charter member of the NIH Pathobiology of Eye Disease 1 study section (review panel) as well as reviewing for public and private funders in the US, Canada, UK, Europe, and Australasia.
ORCiD: 0000-0002-1402-7875

Kamakshi Sishtla
Lab Manager
BS Biology (University of Illinois Urbana-Champaign), 2003
Kamakshi joined the lab in 2011. While she does a bit of everything, she mainly focuses on characterizing antiangiogenic small molecules and ferrochelatase inhibitors.

Dr. Debadatta Mohapatra
Postdoctoral Researcher
MPharm, PhD (IIT-BHU, Varanasi, India), 2023
Debadatta joined the lab at the LDFP, University of Toronto, in September 2024. He will be involved in the development and therapeutic evaluations of novel drug delivery systems for ocular neovascularization and related diseases.

Gabriella Hartman
Indiana University PhD Candidate
BS Pharmaceutical Sciences (University of Mississippi), 2020
Gabriella's PhD project focuses on elucidating pathways underlying retinal neovascularization and evaluating novel, orally bioavailable small molecule inhibitors for treatment of neovascular eye diseases.

Mohammed Ayan Chhipa
PhD Student
MSc Molecular Science (Toronto Metropolitan University), 2024
Mohammed examines how our novel inhibitors affect protein production in downstream pathways, with a particular focus on their role in inhibiting neurovascularization.

Charlotte Campbell
Amgen Scholar 2025
PharmD Student (Memorial University of Newfoundland), 2027
Charlotte’s project investigates the link between inflammatory markers and metabolic changes caused by ferrochelatase inhibition.

April Lu
USRP Student
BSc Pharmacology and Toxicology
(University of Toronto), 2025
April's research examines how Ref-1 inhibition impacts gene expression related to inflammation and oxidative damage to identify mechanisms of oxidative stress pathways in the retina.

Belusi (Bebe) Simelane
USRP Student
BSc Pharmaceutical Chemistry
& Pharmacology
(University of Toronto), 2026
Belusi examines differential gene expression in human endothelial choroidal cells following the administration of a novel APE1/Ref-1 inhibitor targeting neovascularization to inform potential therapeutic interventions for macular degenerative diseases
Graduate, Fellow, and Postdoc Alumni
Halesha Basavarajappa - PhD
Rania Sulaiman - PhD/Postdoc
Michael O'Hare - MSc
Trupti Shetty - PhD/Postdoc
Sheik Pran Babu Sardar Pasha - Postdoc
Bomina Park - PhD/Postdoc
Hannah Whitmore - Visiting PhD Student
Nathan Lambert-Cheatham - Fellow
Nathan Jensen - Fellow
Brandon Jacobs - Fellow
Dhawal Chobisa - Visiting PhD Student
Anbukkarasi Muniyandi - Postdoc
Yang Song - Postdoc​​​​​